GSK and partner Ionis announced positive topline results from two pivotal Phase III trials (B‑Well 1 and B‑Well 2) of bepirovirsen, an antisense oligonucleotide designed to deliver a functional cure for chronic hepatitis B. The studies enrolled more than 1,800 patients across 29 countries and met primary endpoints, the companies said. Bepirovirsen’s aim is sustained loss of hepatitis B surface antigen (HBsAg) off therapy—a "functional cure" distinct from lifelong viral suppression. GSK said it will pursue global regulatory filings based on the data and move toward commercialization planning with Ionis. The success, if confirmed in full datasets and regulatory review, would mark a rare disease‑modifying shift in chronic hepatitis B management and could reshape treatment guidelines and market dynamics for HBV therapeutics.